Objective: We critically reviewed every NICU blood component transfusion (packed erythrocytes, platelets, frozen plasma (FP) and cryoprecipitate) administered during a one-year period. This was done to determine the proportion of transfusions given out of compliance with the Intermountain Healthcare transfusion guidelines, and to look for patterns of noncompliance that could be addressed by quality improvement measures. Result: During 2006 the three NICUs cared for 1759 neonates. Seventeen percent of these received one or more (median 3) erythrocyte transfusions, 4% received one or more (median 3) platelet transfusions, 6% received one or more (median 1) FP infusions and 2% received cryoprecipitate (median 1 dose). Seventy percent of the erythrocyte transfusions were given in compliance with the guidelines, as were 69% of the platelet transfusions, 65% of the FP transfusions and 94% of the cryoprecipitate administrations. Patients who received large numbers of transfusions were more likely to receive transfusion that violated the guidelines. Forty-five percent of patients who received 1 to 3 transfusions received all transfusions within guidelines. However, only 18% of patients who received 4 to 10 transfusions received all within guidelines. No patient who received >10 transfusions received all within the guidelines. Erythrocyte transfusions given early in the hospital course were likely to be within guidelines; 72% (588/818) in the first 29 days were compliant with guidelines, but compliance fell to 61% (144/237) for transfusions administered after 29 days (P ¼ 0.002). About half of the platelet transfusions given early in the hospital course were in violation of guidelines, but after day 9, 83% of platelet transfusions were compliant with guidelines (P ¼ 0.000).
Introduction
Blood component transfusions are an essential part of neonatal intensive care medicine. 1, 2 In fact, transfusions are life saving for many neonatal patients. However, transfusions unquestionably carry risks, and multiple transfusions compound these risks. [3] [4] [5] [6] [7] It is highly probable that some transfusions given to Neonatal Intensive Care Unit (NICU) patients are not necessary. Such transfusions, although ordered with good intentions, might convey no benefits to the recipient, but nevertheless carry risks. Identifying and eliminating any unnecessary transfusions in the NICU would be a step toward better care, lower costs and more careful preservation of blood component resources. 8, 9 Establishing NICU transfusion guidelines has been advocated as a way to improve transfusion practice and reduce unnecessary transfusions. [8] [9] [10] [11] [12] [13] In 2002, Intermountain Healthcare, a not-forprofit healthcare organization in the western United States, established a written set of NICU transfusion guidelines. (These guidelines are provided as supplementary material in the electronic version of this article.) The present study was undertaken as a detailed examination of compliance with these guidelines. Specifically, we critically reviewed every blood component transfusion administered to every NICU patient with a date of birth 1 January 2006 through 31 December 2006, cared for in three perinatal-center-associated level III NICU's of Intermountain Healthcare. For every transfusion given, two or more reviewers examined all available information in the medical record to judge whether or not the transfusion was administered in compliance with vs not in compliance with the Intermountain Healthcare transfusion guidelines. The results of the analysis are presented here.
Methods

Patients
Data were collected from archived Intermountain Healthcare electronic and paper records for patients admitted to the NICU at McKay Dee Hospital, Ogden UT, LDS Hospital, Salt Lake City, UT, and Utah Valley Regional Medical Center, Provo, UT, with a date of birth from 1 January 2006 through 31 December 2006. Complete records were reviewed if the patient received one or more transfusions of any of the following; packed erythrocytes, platelets, frozen plasma (FP) or cryoprecipitate. When more than one transfusion of the same product was administered on the same day, the transfusions were counted as one. The Intermountain Healthcare Institutional Review Board approved the study.
Transfusion guidelines
Guidelines for administering blood transfusions at the Intermountain Healthcare NICUs are shown in the appendix. In brief, the guidelines recommend erythrocyte transfusions if the hematocrit falls below 35% while on mechanical ventilation, below 27% while on supplemental oxygen or with signs of anemia and below 20% in any NICU patient. Platelet transfusions are recommended for three patient categories; (1) if the platelet count falls below 100 000 ml À1 in a patient on extracorporeal membrane oxygenation, with active bleeding or immediately before or immediately after surgery, (2) if the platelet counts falls below 50 000 ml À1 in an 'unstable' NICU patient (mechanical ventilation or vasopressors) and (3) if the platelet count falls below 20 000 ml À1 in a 'stable' NICU patient. FP is recommended only if the patient has clinical hemorrhage and coagulopathic laboratory data. Cryoprecipitate is recommended if disseminated intravascular coagulation is diagnosed by laboratory tests and the patient is not bleeding but has a fibrinogen <100 mg per 100 ml, or if disseminated intravascular coagulation is diagnosed by laboratory tests and there is clinical hemorrhage with a fibrinogen <150 mg per 100 ml.
Electronic data collection and statistical analysis
The program used for data collection was a modified subsystem of Clinical Workstation. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. Data were managed and accessed by authorized data analysts. We expressed transfusions, of each component, as 'transfusions per 1000 patient days' to compare the various transfusion rates at each of the three NICUs. Means and standard deviations were used to express values in groups that were normally distributed, and medians and ranges to express values in groups that were not. Differences in categorical variables were assessed using the Fisher exact test. A Student t-test was used to assess continuous variables. Statistical significance was set as P<0.05.
Results
The three Intermountain Healthcare NICUs involved in this study cared for 1759 neonates born in 2006. Of these, 323 (18%) received a total of 1489 transfusions. Table 1 shows the percent of patients, in each of the three NICUs, who received one or more erythrocyte transfusions, platelet transfusions, FP transfusions and cryoprecipitate administrations. At the three NICUs, the patients who received transfusions were of similar birth weight (1432±759 g (mean±s.d.) at NICU 'A', 1561±863 g at NICU 'B', 1592 ± 949 g at NICU 'C'). The percentage of patients in each NICU that received one or more erythrocyte transfusions ranged from 16% in NICU 'B' to 18% in NICU 'C'. NICU 'A' had the lowest erythrocyte transfusion rate (25/1000 patient days, compared with 37/1000 patient days in NICUs 'B' and 'C'). The percent of patients that received one or more platelet transfusions ranged between 3 and 4%, 5 to 7% received FP transfusions and 1 to 2% received cryoprecipitate.
The number of transfusions per transfused patient at each facility is shown in Table 2 . Rates were similar at the three NICUs, with the exception that NICU 'C' administered more platelet transfusions per transfused patient.
Compliance of each transfusion with the transfusion guidelines is shown in Table 3 . Seventy percent of erythrocyte transfusions and 69% of the platelet transfusions were given in accordance with guidelines. Adherence to FP guidelines varied considerably, and NICU 'B' had particularly poor compliance with the FP guidelines. All three NICUs administered cryoprecipitate in reasonably good compliance with the guidelines.
Patients who received large numbers of transfusions were more likely to receive one or more transfusions outside of guidelines (Table 4) . When 1 to 3 transfusions were given, 45% of patients received all transfusions within guidelines, but when 4 to 10 transfusions were given only 18% of patients had all transfusions given within guidelines. When more than 10 transfusions were administered, none of the patients had all transfusions given within guidelines.
Erythrocyte transfusions given early in the hospital course were more likely to be compliant with the guidelines (Figure 1 ). Seventy-two percent (588/818) of the erythrocyte transfusions given in the first 29 days of life were within guidelines, but compliance fell to 61% (144/229) for those given after 29 days (P ¼ 0.002). The most common situation where erythrocyte transfusion guidelines were violated involved patients who had weaned off mechanical ventilation but still required supplemental oxygen. For such patients, the guidelines call for an erythrocyte transfusion only if the hemoglobin falls below 9 g per 100 ml, but it was common to see a transfusion ordered at hemoglobin levels above 9 g per 100 ml. Platelet transfusions given early in the hospital course were more likely to be non-compliant with the guidelines, just the opposite of the pattern seen with erythrocyte transfusions (Figure 2 ). For instance, 55% of platelet transfusions given in the first 9 days of life were given in accordance with the guidelines, but 83% given after day 9 were compliant with guidelines (P ¼ 0.000). The most common situation where platelet transfusion guidelines were violated involved patients in the first days of life with a platelet count between 50 000 and 100 000 ml À1 and no clinical bleeding. The guidelines call for a platelet transfusion only if the platelet count falls below 50 000 ml À1 , but it was common to see a platelet transfusion ordered at counts above 50 000 ml À1 . No patterns regarding guideline violations were observed for FP or cryoprecipitate administration.
Discussion
Blood component transfusions are common in neonatal intensive care medicine. It has been reported that 20% of patients will, at sometime during their NICU stay, receive one or more transfusions. 14, 15 That figure is concordant with our present study, where 17% of NICU patients received one or more erythrocyte transfusions during their hospital stay, 4% received one or more platelet transfusions, 6% received FP and 2% received cryoprecipitate. While transfusions in the NICU are relatively common, evidence-based criteria for when to administer them are lacking. 16 Consequently, in many NICUs, transfusions are ordered at the discretion of each individual practitioner, and much variation is observed. Many recent studies have reported benefits of instituting written transfusion guidelines for NICU patients. [8] [9] [10] [11] [12] [13] However, much additional study is needed to provide data upon which to base NICU transfusion guidelines.
In 2002, written transfusion guidelines were adopted by the NICUs of Intermountain Healthcare. In the present study, we critically reviewed every blood component transfusion given in 1 year within the three large level III perinatal-center-associated NICUs of Intermountain. The study was undertaken to measure compliance with our transfusion guidelines, and to seek for patterns of non-compliance that could be addressed subsequently as quality improvement initiatives.
Although the patient demographics were similar in the NICUs included in the study, the transfusion rate per 1000 patient days in NICU A was lower than that of B and C. We are uncertain as to why this was, because the blood component selection processes are similar in the three NICUs and none have a directed donor program and all use designated packed red blood cell units.
We observed that, overall, about 30% of the transfusions administered in our NICUs were in violation of our transfusion guidelines. This is better than the 60% violation rate for NICU platelet transfusions reported by Petaja et al., 17 but it indicates to us that we must put forth additional effort. Specifically, we conclude that effort is needed in two areas. First, the transfusion guidelines that are being violated most commonly must be critically reexamined. Second, systems must be instituted to better regulate non-emergent blood product dispensing to the NICU. Such systems could remind practitioners of the guidelines in real-time, while tightening control and reducing the potential of unnecessary transfusions, for reasons such as the impending expiration of a crossed-matched packed red blood cell unit. Such systems could also record the explanation when a transfusion is ordered in violation of the guidelines. Figure 1 The percent of erythrocyte transfusions that were given outside of guidelines is shown in association with the day of life the transfusion was given.
The numbers above the bars refer to the total number of transfusions given on that day of life. Figure 2 The percent of platelet transfusions that were given outside of guidelines is shown in association with the day of life the transfusion was given. The numbers above the bars refer to the total number of transfusions given on that day of life.
Regarding the first of these two efforts, the most common violations we saw involved; (1) platelet transfusions in the first week of life, where non-bleeding patients received transfusions because of platelet counts in the 50 000 to 100 000 ml À1 range, whereas the guidelines recommend platelet transfusions only if the count is <50 000 ml À1 and (2) erythrocyte transfusions given when patients were receiving supplemental oxygen alone. These patients received transfusions when the hemoglobin was in the range of 9 to 12 g per 100 ml, whereas the guidelines recommend erythrocyte transfusion only if the hemoglobin falls below 9 g per 100 ml.
We are not aware of any evidence that supports giving platelet transfusions to non-bleeding NICU patients with a platelet count >50 000 ml À1 , unless they are anticoagulated for extracorporeal membrane oxygenation or are at an immediately pre-or postoperative stage. 12, 18, 19 Future randomized trials, using different transfusion 'trigger levels' would be helpful in assessing this issue. Similarly, we are aware of little evidence to support giving erythrocyte transfusions to non-bleeding, non-mechanically ventilated NICU patients with a hemoglobin >9 g per 100 ml. Bell et al. 20 found an increase in intracranial parenchymal bleeding in neonates between 500 and 1300 g when treated using a restricted erythrocyte transfusion guideline, but this has not been observed by others. Furthermore, this type of hemorrhage almost always occurs during the few days after birth, and the common guideline violations we observed occurred several weeks after birth. Here again, future randomized trials using different erythrocyte transfusion trigger levels would be helpful.
Very little evidence can be cited regarding the benefits of FP infusions for non-bleeding neonates. Stanworth and co-workers reviewed 12 studies of FP use in the NICU, and concluded that no benefit of FP could be identified in non-bleeding patients, for its use either as a volume expander, for immunological effects or for preventing hemorrhage. 21, 22 In the present study, we identified 456 transfusions, during a one-year period, that were given in violation of our transfusion guidelines. We speculate that some of these transfusions conveyed little or no benefit to the recipient, but each unneeded transfusion conveyed known and unknown risks. Patients receiving multiple transfusions are clearly a group where an opportunity exists to improve transfusion practice. In fact, we found no patients that receive more than 10 transfusions where all were given within the guidelines. We speculate that this is simply a multiplier effect. Future randomized controlled trials are needed to provide a more complete evidence-base for NICU transfusion practice, and to quantify short and long-term risks and benefits of blood component therapy.
We maintain that useful next steps toward improving our NICU transfusion practice will be as follows: (1) devising studies to assess any benefits of platelet transfusions to non-bleeding neonates with platelet counts in the 50 000 to 100 000 ml À1 range, (2) devising studies to assess any benefits of erythrocyte transfusions to nonbleeding neonates on supplemental O 2 , but not on mechanical ventilation, with a hemoglobin concentration >9 g per 100 ml and (3) devising interactive, electronic, rapid means of regulating blood component dispensing to the NICU, linking informatics and decision support with blood bank technology.
